Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06585488
Title A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors BeiGene
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | NZL | ESP | AUS


No variant requirements are available.